• 2024-05-15
    InnolakeBio’s ADC Product ILB-3101 (globally the first anti-B7H3 ADC with Eribulin as payload) Approved for Clinical Trial
    SEE MORE
  • 2024-03-28
    Innolake Filed IND for B7H3 ADC(ILB-3101) and will Present Its Pre-Clinical Study Result at 2024 AACR
    SEE MORE
<
123
>